Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer-A definite conclusion?

Semin Oncol. 2017 Apr;44(2):129-131. doi: 10.1053/j.seminoncol.2017.07.002. Epub 2017 Jul 29.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Bevacizumab
  • Colorectal Neoplasms*
  • Humans

Substances

  • Bevacizumab